NASDAQ:IRD Opus Genetics (IRD) Stock Price, News & Analysis $4.26 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.29 +0.03 (+0.75%) As of 05/22/2026 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Opus Genetics Stock (NASDAQ:IRD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Opus Genetics alerts:Sign Up Key Stats Today's Range$4.19▼$4.3850-Day Range$4.26▼$5.7552-Week Range$0.90▼$5.81Volume569,454 shsAverage Volume1.00 million shsMarket Capitalization$346.76 millionP/E RatioN/ADividend YieldN/APrice Target$10.18Consensus RatingModerate Buy Company Overview Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan. Read More Opus Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreIRD MarketRank™: Opus Genetics scored higher than 66% of companies evaluated by MarketBeat, and ranked 235th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOpus Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 12 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialOpus Genetics has a consensus price target of $10.18, representing about 139.0% upside from its current price of $4.26.Amount of Analyst CoverageOpus Genetics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Opus Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Opus Genetics are expected to grow in the coming year, from ($1.00) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Opus Genetics is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Opus Genetics is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Opus Genetics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.17% of the float of Opus Genetics has been sold short.Short Interest Ratio / Days to CoverOpus Genetics has a short interest ratio ("days to cover") of 2.16, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Opus Genetics has recently increased by 10.65%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOpus Genetics does not currently pay a dividend.Dividend GrowthOpus Genetics does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment0.40 News SentimentOpus Genetics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Opus Genetics this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for IRD on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Opus Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,777,278.00 in company stock.Percentage Held by Insiders11.70% of the stock of Opus Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions14.97% of the stock of Opus Genetics is held by institutions.Read more about Opus Genetics' insider trading history. Receive IRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opus Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRD Stock News HeadlinesLeerink Partners initiates coverage of Opus Genetics (IRD) with outperform recommendationMay 22 at 1:46 PM | msn.comFighting Blindness Foundation Sells 1,700,000 Shares of Opus Genetics (NASDAQ:IRD) StockMay 22 at 4:21 AM | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.May 25 at 1:00 AM | Banyan Hill Publishing (Ad)Opus Genetics (NASDAQ:IRD) Director Sells $7,395,000.00 in StockMay 21, 2026 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Opus Genetics (IRD)May 15, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Opus Genetics (IRD), MaxCyte (MXCT) and Solid Biosciences (SLDB)May 14, 2026 | theglobeandmail.comOpus Genetics (NASDAQ:IRD) Price Target Lowered to $11.00 at Citizens JmpMay 14, 2026 | americanbankingnews.comJoseph Schachle Sells 4,697 Shares of Opus Genetics (NASDAQ:IRD) StockApril 28, 2026 | insidertrades.comSee More Headlines IRD Stock Analysis - Frequently Asked Questions How have IRD shares performed this year? Opus Genetics' stock was trading at $2.01 at the beginning of the year. Since then, IRD shares have increased by 111.9% and is now trading at $4.26. How were Opus Genetics' earnings last quarter? Opus Genetics, Inc. (NASDAQ:IRD) issued its earnings results on Tuesday, May, 12th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.59. The company had revenue of $2.16 million for the quarter, compared to analyst estimates of $2.93 million. Opus Genetics had a negative net margin of 892.36% and a negative trailing twelve-month return on equity of 338.88%. Who are Opus Genetics' major shareholders? Opus Genetics' top institutional shareholders include ADAR1 Capital Management LLC (2.27%), Renaissance Technologies LLC (0.09%), Regency Capital Management Inc. DE (0.10%) and Bank of America Corp DE (0.08%). Insiders that own company stock include Fighting Blindness Foundation, Cam Gallagher, Cam Gallagher, George Magrath, Benjamin R Yerxa, Benjamin R Yerxa, Robert E Gagnon, Ashwath Jayagopal, Joseph K Schachle and Rabourn Amy Zaremba. View institutional ownership trends. How do I buy shares of Opus Genetics? Shares of IRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2026Today5/25/2026Investor update6/16/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 IRD's financial health is in the Green zone, according to TradeSmith. IRD has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IRD Previous SymbolNASDAQ:IRD CIK1228627 Webwww.ocuphire.com Phone248-957-9024Fax240-268-5310Employees14Year Founded2018Price Target and Rating Average Price Target for Opus Genetics$10.18 High Price Target$15.00 Low Price Target$7.00 Potential Upside/Downside+139.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.59 million Net Margins-892.36% Pretax Margin-892.36% Return on Equity-338.88% Return on Assets-191.21% Debt Debt-to-Equity RatioN/A Current Ratio7.13 Quick Ratio7.13 Sales & Book Value Annual Sales$14.20 million Price / Sales24.42 Cash FlowN/A Price / Cash FlowN/A Book Value($0.56) per share Price / Book-7.61Miscellaneous Outstanding Shares81,400,000Free Float71,873,000Market Cap$346.76 million OptionableN/A Beta0.62 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:IRD) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
